What is Delfi Diagnostics?
DELFI Diagnostics is at the forefront of early cancer detection, leveraging its proprietary Fragmentomics Platform. This innovative technology employs advanced machine learning and next-generation sequencing to analyze cell-free DNA from liquid biopsy samples. Their offerings, including FirstLookLung for healthcare providers and patients, and DELFI-TF for treatment monitoring, are designed to serve healthcare systems, pharmaceutical partners, and patients with scalable and effective cancer screening solutions. The company's commitment to transforming cancer care and improving patient outcomes is driven by a leadership team with deep expertise in genomics, AI, and cancer biology.
How much funding has Delfi Diagnostics raised?
Delfi Diagnostics has raised a total of $325M across 2 funding rounds:
Series A
$100M
Series B
$225M
Series A (2021): $100M with participation from Samsara Biocapital, Illumina Ventures, Menlo Ventures, OrbiMed Advisors LLC, AV8 Ventures, and Windham Venture Partners
Series B (2022): $225M led by Point72, Eli Lilly and Company Pvt, Brown Advisory, and DFJ Growth
Key Investors in Delfi Diagnostics
Point72
Point72 is a private investment management firm known for its diverse investment strategies across various asset classes.
Eli Lilly and Company Pvt
Eli Lilly and Company Pvt is a subsidiary of the global biopharmaceutical giant, focusing on developing advanced treatment options for chronic diseases.
DFJ Growth
DFJ Growth is a late-stage global venture capital firm that provides capital to rapidly scaling technology companies poised for market leadership.
What's next for Delfi Diagnostics?
The substantial enterprise-level funding indicates Delfi Diagnostics is poised for significant scaling and further development of its groundbreaking cancer detection technologies. This capital infusion will likely accelerate market penetration, expand research and development efforts, and strengthen strategic partnerships within the healthcare and pharmaceutical sectors. The company's focus on liquid biopsy and AI-driven analysis positions it for continued growth and impact in the oncology diagnostics landscape.
See full Delfi Diagnostics company page
